PAHO Urges Countries to Boost Diphtheria Vaccination Amid Rising Cases in the Americas

June 16, 2026 — The Pan American Health Organization (PAHO) has declared a regional alert over a 37% increase in diphtheria cases across the Americas in the first half of 2026, with outbreaks reported in Venezuela, Haiti, and parts of Central America. The surge—linked to vaccination coverage drops below 80% in high-risk populations—has prompted PAHO to urge countries to reinforce immunization campaigns and strengthen surveillance systems. Diphtheria, a preventable bacterial infection caused by Corynebacterium diphtheriae, remains a critical public health threat due to its 10–20% mortality rate in untreated cases, according to the latest PAHO epidemiological bulletin.

Key Clinical Takeaways:

Vaccination gaps are the primary driver of the resurgence, with PAHO reporting 12 confirmed cases in Venezuela alone since January 2026, compared to just 3 in the same period last year.
Diphtheria’s pathogenesis—toxigenic strains producing exotoxin that damages heart, nerves, and kidneys—requires immediate antitoxin treatment alongside antibiotics (e.g., penicillin or erythromycin) for severe cases.
Healthcare providers must prioritize booster campaigns for adolescents and adults, as waning immunity in these groups contributes to transmission clusters.

Why Is Diphtheria Spreading Now?

Three interconnected factors explain the current outbreak:

Declining immunization rates: PAHO data shows vaccination coverage in Venezuela dropped from 85% in 2020 to 68% in 2025, with similar trends in Haiti and Honduras. “This is a direct consequence of disrupted healthcare systems and misinformation campaigns downplaying vaccine necessity,” said Dr. María Elena Rodríguez, PAHO’s regional immunization advisor.
Strain evolution: A 2025 study in The Journal of Infectious Diseases identified emerging toxigenic variants with higher virulence, funded by the Bill & Melinda Gates Foundation and led by researchers at the University of São Paulo. These strains evade partial immunity from older vaccines.
Cross-border mobility: The Mercosur health bloc reported 5 confirmed cases in Brazil and Paraguay linked to travelers from Venezuela, highlighting the need for regional coordination.

How Diphtheria’s Toxin Works—and Why Vaccination Is the Only Defense

Corynebacterium diphtheriae secretes an A-B toxin that inhibits protein synthesis in host cells, leading to pseudomembrane formation in the throat and systemic organ failure. The DTaP vaccine (diphtheria-tetanus-acellular pertussis) remains the gold standard, with 95% efficacy after three doses, per the World Health Organization’s 2024 Vaccine Position Paper. However, booster doses every 10 years are critical for adults, as immunity wanes.

“The resurgence is a textbook case of herd immunity collapse,” noted Dr. Carlos Mendoza, infectious disease epidemiologist at the University of Miami. “We’re seeing clusters in low-income urban areas where vaccine hesitancy intersects with poor sanitation. The good news? Antitoxin and antibiotics still work, but the window for intervention is narrowing.”

What Healthcare Providers Need to Do Now

Clinicians and public health officials must act on three fronts:

1. Diagnostic Vigilance

Diphtheria’s symptoms—sore throat, fever, and grayish throat membranes—can mimic strep throat or mononucleosis. The Elek test (gold standard for toxin detection) has a 98% sensitivity but requires lab infrastructure often lacking in outbreak zones. “In resource-limited settings, rapid antigen tests like the SD Bioline Diphtheria Ag (sensitivity: 89%) can bridge the gap,” said Dr. Rodríguez. For immediate triage, providers should:

Order throat swabs for PCR confirmation in suspected cases (turnaround: 24–48 hours).
Administer diphtheria antitoxin (equine origin) within 48 hours of symptom onset to neutralize circulating toxin.
Prescribe penicillin G (100,000–200,000 units/kg/day) for 14 days or erythromycin for penicillin-allergic patients.

2. Vaccination Campaigns

PAHO recommends targeted catch-up campaigns for:

Adolescents (11–18 years): Many missed boosters during the pandemic.
Adults 19–64: 40% of U.S. adults lack documented boosters, per CDC data.
Healthcare workers: High exposure risk; 15% of Venezuelan healthcare workers tested in 2025 lacked immunity.

For rapid deployment, providers should partner with:

[Vaccine Distribution Specialists] – Logistics firms like [BioNTech Vaccine Logistics] or [Pfizer Global Supply Chain] to ensure cold-chain integrity for DTaP shipments.
[Mobile Vaccination Clinics] – Organizations such as [Doctors Without Borders’ Immunization Teams] or [PAHO’s Rapid Response Units] for hard-to-reach populations.

3. Legal and Compliance Support

Countries facing outbreaks may need to temporarily mandate vaccinations for school attendance or travel, a move requiring health law expertise. “The Mercosur bloc is already drafting emergency protocols to align with WHO’s International Health Regulations (2005),” said Dr. Mendoza. Providers navigating these challenges should consult:

[Healthcare Compliance Attorneys] – Firms like [McDermott Will & Emery’s Global Health Practice] specialize in cross-border vaccination mandates.
[Public Health Law Experts] – Institutions such as [Harvard Law School’s Petrie-Flom Center] offer pro bono guidance on emergency immunization policies.

What Happens Next: The Road Ahead

The next 12 months will determine whether the Americas can halt the resurgence or face a prolonged outbreak. Key milestones:

July 2026: PAHO’s Emergency Operations Center will deploy 10 rapid-response teams to Venezuela, Haiti, and Brazil.
Q4 2026: A next-generation DTaP vaccine (funded by Gavi, the Vaccine Alliance) may enter Phase III trials, offering longer-lasting immunity.
2027: WHO’s Strategic Advisory Group of Experts (SAGE) will reassess diphtheria vaccination schedules, potentially recommending booster intervals every 7–10 years.

For patients and providers in high-risk regions, proactive measures are critical. Those with undocumented vaccination histories should:

Seek serum antibody testing via [CLIA-certified labs like LabCorp or Quest Diagnostics].
Consult [infectious disease specialists] for personalized vaccination plans, especially if traveling to outbreak zones.

As Dr. Rodríguez emphasized, “This isn’t just about vaccines—it’s about systems. Countries with strong primary care networks, like Canada and Uruguay, have contained outbreaks. Those without must act now.”

Disclaimer: The information provided in this article is for educational and scientific communication purposes only and does not constitute medical advice. Always consult with a qualified healthcare provider regarding any medical condition, diagnosis, or treatment plan.